Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab in real-world advanced hepatocellular carcinoma after REACH-2
jRCTs031190236Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of ramucirumab in hepatocellular carcinoma (HCC), sponsored by Eli Lilly and Company. Primary endpoint: Progression free survival ratio after six months. Started May 2020; status: completed.
02
Drugs
ramucirumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCTs031190236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190236.